NCT06597721View on ClinicalTrials.gov

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

ADCE-T02

Administered intravenously

Trial Locations (9)

2031

RECRUITING

Scientia Clinical Research, Randwick

3144

RECRUITING

Cabrini Hospital, Malvern

3199

RECRUITING

Peninsula and South Eastern Haematology and Oncology Group (PSEHOG), Frankston

5042

RECRUITING

Southern Oncology Clinical Research Unit, Bedford Park

6009

RECRUITING

Linear Clinical Research, Nedlands

72758

RECRUITING

Highlands Oncology Group, Rogers

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

START San Antonio, San Antonio

06520

RECRUITING

Yale University Cancer Center, New Haven

Sponsors

Lead Sponsor

Adcendo ApS
All Listed Sponsors
lead

Adcendo ApS

INDUSTRY

NCT06597721 - ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | Biotech Hunter | Biotech Hunter